Ironwood Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Ironwood Pharmaceuticals (IRWD).

Price Target Range — 8 Quarters

Analyst Consensus — 6 Analysts

2S.Buy

2Buy

2Hold

Consensus RatingMarket Outperform# Analysts6Avg. Consensus PT$8Upside to Avg. PT+138.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Feb 26, 2026	Citizens	Jason N. Butler	PT Raise	Market Outperform	$8→$10
Jan 5, 2026	Wells Fargo	Mohit Bansal	PT Raise	Equal-Weight	$3→$5
Jan 5, 2026	Citizens	Jason Butler	Upgrade	Market Perform→Market Outperform	$8
Nov 11, 2025	Wells Fargo	Mohit Bansal	PT Raise	Equal-Weight	$1→$3
Apr 15, 2025	Wells Fargo	Mohit Bansal	Downgrade	Overweight→Equal-Weight	$7→$1
Apr 15, 2025	Jefferies	Amy Li	Downgrade	Buy→Hold	$8→$1
Apr 14, 2025	Leerink Partners	Faisal Khurshid	PT Cut	Market Perform	$3→$1
Jan 30, 2025	JMP Securities	Roy Buchanan	PT Cut	Market Outperform	$23→$14
Jan 22, 2025	Craig-Hallum	Chase Knickerbocker	PT Cut	Buy	$10→$8
Sep 9, 2024	Leerink Partners	Faisal Khurshid	Initiate	Market Perform	$5
Aug 9, 2024	Wells Fargo	Mohit Bansal	PT Cut	Overweight	$14→$12
Aug 9, 2024	Craig-Hallum	Chase Knickerbocker	PT Cut	Buy	$14→$10
May 10, 2024	Craig-Hallum	Chase Knickerbocker	PT Cut	Buy	$18→$14
Mar 1, 2024	Wells Fargo	Mohit Bansal	PT Cut	Overweight	$20→$14
Feb 16, 2024	Piper Sandler	David Amsellem	PT Raise	Overweight	$20→$21
Jan 17, 2024	Craig-Hallum	Chase Knickerbocker	Initiate	Buy	$21
Dec 14, 2023	Wells Fargo	Mohit Bansal	Initiate	Overweight	$20

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Citizens Maintains Market Outperform on Ironwood Pharmaceuticals, Raises Price Target to $10

Citizens analyst Jason N. Butler maintains Ironwood Pharmaceuticals (NASDAQ:IRWD) with a Market Outperform and raises the price target from $8 to $10.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Ironwood Pharmaceuticals, Raises Price Target to $5

Wells Fargo analyst Mohit Bansal maintains Ironwood Pharmaceuticals (NASDAQ:IRWD) with a Equal-Weight and raises the price target from $3 to $5.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Ironwood Pharmaceuticals, Raises Price Target to $3

Wells Fargo analyst Mohit Bansal maintains Ironwood Pharmaceuticals (NASDAQ:IRWD) with a Equal-Weight and raises the price target from $1 to $3.

Benzinga Newsdesk

PRO
Wells Fargo Downgrades Ironwood Pharmaceuticals to Equal-Weight, Lowers Price Target to $1

Wells Fargo analyst Mohit Bansal downgrades Ironwood Pharmaceuticals (NASDAQ:IRWD) from Overweight to Equal-Weight and lowers the price target from $7 to $1.

Benzinga Newsdesk

This General Motors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Avi Kapoor

PRO
Jefferies Downgrades Ironwood Pharmaceuticals to Hold, Lowers Price Target to $0.7

Jefferies analyst Amy Li downgrades Ironwood Pharmaceuticals (NASDAQ:IRWD) from Buy to Hold and lowers the price target from $8 to $0.7.

Benzinga Newsdesk

Ironwood Pharmaceuticals Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Ironwood Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Citizens Maintains Market Outperform on Ironwood Pharmaceuticals, Raises Price Target to $10

PRO
Wells Fargo Maintains Equal-Weight on Ironwood Pharmaceuticals, Raises Price Target to $5

PRO
Wells Fargo Maintains Equal-Weight on Ironwood Pharmaceuticals, Raises Price Target to $3

PRO
Wells Fargo Downgrades Ironwood Pharmaceuticals to Equal-Weight, Lowers Price Target to $1

This General Motors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

PRO
Jefferies Downgrades Ironwood Pharmaceuticals to Hold, Lowers Price Target to $0.7

People Also Watch

People Also Watch

Ironwood Pharmaceuticals Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Ironwood Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROCitizens Maintains Market Outperform on Ironwood Pharmaceuticals, Raises Price Target to $10

PROWells Fargo Maintains Equal-Weight on Ironwood Pharmaceuticals, Raises Price Target to $5

PROWells Fargo Maintains Equal-Weight on Ironwood Pharmaceuticals, Raises Price Target to $3

PROWells Fargo Downgrades Ironwood Pharmaceuticals to Equal-Weight, Lowers Price Target to $1

This General Motors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

PROJefferies Downgrades Ironwood Pharmaceuticals to Hold, Lowers Price Target to $0.7

People Also Watch

People Also Watch

PRO
Citizens Maintains Market Outperform on Ironwood Pharmaceuticals, Raises Price Target to $10

PRO
Wells Fargo Maintains Equal-Weight on Ironwood Pharmaceuticals, Raises Price Target to $5

PRO
Wells Fargo Maintains Equal-Weight on Ironwood Pharmaceuticals, Raises Price Target to $3

PRO
Wells Fargo Downgrades Ironwood Pharmaceuticals to Equal-Weight, Lowers Price Target to $1

PRO
Jefferies Downgrades Ironwood Pharmaceuticals to Hold, Lowers Price Target to $0.7